Covid symptoms have largely stayed the same over the last few years: cough, congestion, fever, a sore throat, nausea, ...

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...

A detailed examination of how patients respond to the drug at various times and doses provides greater context to a recent ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

“We are about five years into the pandemic, and yet there are not yet any federally-approved treatments for long Covid,” ...

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

New findings from the NIH RECOVER Initiative suggest that SARS-CoV-2 infection may be associated with an increased risk of ME ...

Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), comments on the many viruses that could cause pandemics that are going around already.